Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
corpus cavernosum
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "corpus cavernosum" in MCE Product Catalog:
12
12 Publications Verification
Synonyms: (-)-Apomorphine
Target:
Dopamine Receptor Monoamine Oxidase Reactive Oxygen Species (ROS) JNK ERK Amyloid-β Tau Protein MMP
Research Areas:
Neurological Disease Inflammation/Immunology Endocrinology Cancer
Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
8
Target:
Research Areas:
Phentolamine hydrochloride is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine hydrochloride antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine hydrochloride reduces systemic vascular resistance and increases cardiac output. Phentolamine hydrochloride improves erectile dysfunction. Phentolamine hydrochloride can be used for the research of erectile dysfunction .
1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Moxisylyte (Thymoxamine) hydrochloride is a selective α1A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy .
Category:
Alkaloids Other Alkaloids Alpinia officinarum Hance Plants Disease Research Fields Endocrinology Zingiberaceae
Target:
Target:
Cat. No.: HY-W705784A
CAS No.: 212500-03-3
Target:
Research Areas:
T-1032 is a selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 1.0 nM. T-1032 shows relaxant effect on isolated rabbit corpus cavernosum. T-1032 can be used for the research of erectile dysfunction .
Cat. No.: HY-W705784
CAS No.: 212500-02-2
Target:
Research Areas:
T-1032 free base is a selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 1.0 nM. T-1032 free base shows relaxant effect on isolated rabbit corpus cavernosum. T-1032 free base can be used for the research of erectile dysfunction .
Cat. No.: HY-19548
CAS No.: 63107-40-4
Target:
Research Areas:
BEC, an arginine analogue, is a slow-binding competitive inhibitor of the binuclear manganese metalloenzyme arginase. BEC enhances substrate flux to NO synthase, thereby enhancing NO-dependent smooth muscle relaxation in the corpus cavernosum, and enhances penile erection .
Cat. No.: HY-107022
CAS No.: 296250-53-8
Target:
Research Areas:
BMS-341400 is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM. BMS-341400 reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 can be used to study erectile dysfunction.
Cat. No.: HY-18252A
CAS No.: 330784-48-0
Synonyms: TA1790 dibenzenesulfonate
Category:
Target:
Cat. No.: HY-P11642A
Research Areas:
Cat. No.: HY-107022A
CAS No.: 296250-54-9
Target:
Research Areas:
BMS-341400 mesylate is a selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM. BMS-341400 mesylate reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 mesylate can be used to study erectile dysfunction .
Cat. No.: HY-18252R
CAS No.: 330784-47-9
Synonyms: TA1790 (Standard)
Category:
Cat. No.: HY-18252S1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Moxisylyte (Thymoxamine) is a selective α1A-adrenergic receptor antagonist. Moxisylyte competitively antagonizes the activation mediated by norepinephrine. Moxisylyte relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte is applicable to research related to erectile dysfunction and multiple system atrophy .
Cat. No.: HY-A0066AR
CAS No.: 59-97-2
Synonyms: Imidaline hydrochloride (Standard); NSC35110 hydrochloride (Standard)
Cat. No.: HY-44667
CAS No.: 35231-36-8
Target:
Research Areas:
Deacetylmoxisylyte is an orally active metabolite in plasma of the prodrug Moxisylyte. Deacetylmoxisylyte exhibits similar affinity and selectivity for rabbit corpus cavernosum and urethra. Deacetylmoxisylyte has IC50 values of 400 and 1200 nM for alpha-1 and alpha-2 adrenoceptors .
Cat. No.: HY-114797
CAS No.: 261769-44-2
Target:
Research Areas:
PDE5-IN-16 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 0.8 nM. PDE5-IN-16 enhances the relaxation of corpus cavernosum tissue strips. PDE5-IN-16 is applicable for the research of erectile dysfunction .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
